Alexey Eliseev - RXi Pharmaceuticals Chief Business Officer
Executive
Dr. Alexey Eliseev serves as Chief Business Officer of the Company. He was previously the Founder and Chief Executive Officer of MirImmune. Dr. Eliseevs career includes over twenty years of experience in academia, biotechnology industry and VC. He received his Ph.D. in Bioorganic Chemistry from Moscow State University and MBA from the MIT Sloan School of Management. Alexey was working in the U.S. and Europe since 1992. Following three years of postdoctoral research in Germany and in the U.S., he joined the faculty at SUNY Buffalo in 1995 where he was awarded tenure in 2000. In 1999 he cofounded the company Therascope later Alantos Pharmaceuticals, with a number of prominent founders including French Nobel Laureate JeanMarie Lehn. He then became CTO of Alantos and President of Alantoss U.S. division. Alantos was acquired by Amgen in 2007. Dr. Eliseev was also among the founders of AC Immune and Boston BioCom LLC. Over the recent years he has worked with Maxwell Biotech Venture Fund as its Managing Director and ran the investment activity of the fund in the United States. Dr. Eliseev is a member of the board of directors of BioNevia Pharmaceuticals. since 2017.
Age | 50 |
Tenure | 7 years |
Phone | 508-767-3861 |
Web | http://www.rxipharma.com |
RXi Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (96.79) % which means that it has lost $96.79 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (294.79) %, meaning that it created substantial loss on money invested by shareholders. RXi Pharmaceuticals' management efficiency ratios could be used to measure how well RXi Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | EXECUTIVE Age | ||
Tiang Tan | Western Digital | 54 | |
Cecilia Bilesio | Tenaris SA ADR | N/A | |
Carolyn Bass | Asure Software | N/A | |
Renato Catallini | Tenaris SA ADR | 58 | |
Paola Mazzoleni | Tenaris SA ADR | 43 | |
Claus Morch | Awilco Drilling PLC | 66 | |
Kate MBA | Rani Therapeutics Holdings | N/A | |
Gabriel Podskubka | Tenaris SA ADR | 50 | |
Antonio Caprera | Tenaris SA ADR | 59 | |
Gene Zamiska | Western Digital | 62 | |
Eric Groen | Rani Therapeutics Holdings | 53 | |
Michele Briotta | Tenaris SA ADR | 47 | |
Guillermo Moreno | Tenaris SA ADR | 53 | |
Peter Andrew | Western Digital | N/A | |
Sergio Tosato | Tenaris SA ADR | 65 | |
Scott Davis | Western Digital | N/A | |
Arvinder Dhalla | Rani Therapeutics Holdings | N/A | |
Cathrine Haavind | Awilco Drilling PLC | N/A | |
German Cura | Tenaris SA ADR | 57 | |
Sergio Maza | Tenaris SA ADR | 68 | |
Robert Soderbery | Western Digital | 58 |
Management Performance
Return On Equity | -294.79 | |||
Return On Asset | -96.79 |
RXi Pharmaceuticals Leadership Team
Elected by the shareholders, the RXi Pharmaceuticals' board of directors comprises two types of representatives: RXi Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RXi. The board's role is to monitor RXi Pharmaceuticals' management team and ensure that shareholders' interests are well served. RXi Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, RXi Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Geert Cauwenbergh, President CEO, Director | ||
Robert Bitterman, Director | ||
Pamela Pavco, Chief Devel. Officer | ||
Keith Brownlie, Director | ||
Jonathan Freeman, Independent Director | ||
Gerrit Dispersyn, Chief Development Officer | ||
Curtis Lockshin, Director | ||
Paul Dorman, Independent Director | ||
Alexey Eliseev, Chief Business Officer | ||
Tamara McGrillen, IR Contact Officer |
RXi Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is RXi Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -294.79 | |||
Return On Asset | -96.79 | |||
Current Valuation | (1.77 M) | |||
Shares Outstanding | 18.16 M | |||
Shares Owned By Insiders | 3.78 % | |||
Shares Owned By Institutions | 10.08 % | |||
Number Of Shares Shorted | 814.04 K | |||
Price To Earning | (0.54) X | |||
Price To Book | 0.84 X | |||
Price To Sales | 39.20 X |
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in RXi Stock
If you are still planning to invest in RXi Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the RXi Pharmaceuticals' history and understand the potential risks before investing.
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume |